BR112015019590A2 - derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv - Google Patents

derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv

Info

Publication number
BR112015019590A2
BR112015019590A2 BR112015019590A BR112015019590A BR112015019590A2 BR 112015019590 A2 BR112015019590 A2 BR 112015019590A2 BR 112015019590 A BR112015019590 A BR 112015019590A BR 112015019590 A BR112015019590 A BR 112015019590A BR 112015019590 A2 BR112015019590 A2 BR 112015019590A2
Authority
BR
Brazil
Prior art keywords
hiv
alkyl
treatment
acid derivatives
betulinic acid
Prior art date
Application number
BR112015019590A
Other languages
English (en)
Portuguese (pt)
Inventor
Regueiro-Ren Alicia
Swidorski Jacob
Chen Jie
Xu Li
A Meanwell Nicholas
A Hartz Richard
Sit Sing-Yuen
Chen Yan
Liu Zheng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112015019590A2 publication Critical patent/BR112015019590A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112015019590A 2013-02-25 2014-02-21 derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv BR112015019590A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361768630P 2013-02-25 2013-02-25
PCT/US2014/017688 WO2014130810A1 (en) 2013-02-25 2014-02-21 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv

Publications (1)

Publication Number Publication Date
BR112015019590A2 true BR112015019590A2 (pt) 2017-07-18

Family

ID=50288267

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019590A BR112015019590A2 (pt) 2013-02-25 2014-02-21 derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv

Country Status (15)

Country Link
US (1) US9249180B2 (https=)
EP (1) EP2958930A1 (https=)
JP (1) JP6186012B2 (https=)
KR (1) KR20150121712A (https=)
CN (1) CN105102468A (https=)
AR (1) AR094876A1 (https=)
AU (1) AU2014218754B2 (https=)
BR (1) BR112015019590A2 (https=)
CA (1) CA2902513A1 (https=)
EA (1) EA027861B1 (https=)
IL (1) IL240739A0 (https=)
MX (1) MX2015010354A (https=)
SG (1) SG11201506445PA (https=)
TW (1) TW201444862A (https=)
WO (1) WO2014130810A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
RU2017134461A (ru) * 2015-04-14 2019-05-14 ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД Способы получения ингибитора созревания HIV
PL3371171T3 (pl) 2015-11-02 2024-03-25 Blueprint Medicines Corporation Inhibitory RET
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ret之抑制劑
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018044838A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
CN106749486A (zh) * 2016-11-30 2017-05-31 沈阳化工大学 一种以乙二胺为连接臂的齐墩果酸衍生物及其应用
RU2020113341A (ru) 2017-09-14 2021-10-15 Феникс Байотекнолоджи, Инк. Способ и композиция для лечения вирусной инфекции
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
SI3773589T1 (sl) 2018-04-03 2024-03-29 Blueprint Medicines Corporation Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo
SI3924361T1 (sl) 2019-02-11 2024-02-29 Hetero Labs Limited Novi derivati triterpena kot zaviralci virusa hiv
CN111362923A (zh) * 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
CN111440151A (zh) * 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
JP7153083B2 (ja) 2020-03-31 2022-10-13 フェニックス・バイオテクノロジー・インコーポレイテッド コロナウイルス感染を治療するための方法および組成物
JP2023527412A (ja) 2020-05-29 2023-06-28 ブループリント メディシンズ コーポレイション プラルセチニブの固体形態

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
CN103038245B (zh) 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
KR101886467B1 (ko) * 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
PL2670764T3 (pl) * 2011-01-31 2016-02-29 Bristol Myers Squibb Co C-28 aminy zmodyfikowanych C-3 pochodnych kwasu betulinowego jako inhibitory dojrzewania HIV
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Also Published As

Publication number Publication date
TW201444862A (zh) 2014-12-01
JP6186012B2 (ja) 2017-08-23
AR094876A1 (es) 2015-09-02
EA201591545A1 (ru) 2015-12-30
US9249180B2 (en) 2016-02-02
MX2015010354A (es) 2015-10-09
US20140243298A1 (en) 2014-08-28
JP2016509062A (ja) 2016-03-24
CA2902513A1 (en) 2014-08-28
WO2014130810A1 (en) 2014-08-28
SG11201506445PA (en) 2015-09-29
AU2014218754B2 (en) 2017-04-20
CN105102468A (zh) 2015-11-25
AU2014218754A1 (en) 2015-10-15
KR20150121712A (ko) 2015-10-29
EP2958930A1 (en) 2015-12-30
IL240739A0 (en) 2015-10-29
EA027861B1 (ru) 2017-09-29

Similar Documents

Publication Publication Date Title
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
BR112014010105A2 (pt) aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
BR112015018491A2 (pt) triterpenoides c-19-modificados com atividade inibidora de maturação de hiv
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
EA201792597A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BR112014006559A2 (pt) derivados do ácido betulínico com atividade antiviral
JOP20170029B1 (ar) C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements